Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06109779 · ClinicalTrials.gov registry record · Phase 3

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
757
Enrollment target
20
Study locations

NCT06109779 is a Phase 3 study of Biliary Tract Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 757 participants, above the 218-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (247% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06109779, a Phase 3 study of Biliary Tract Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
757 participants
Enrollment target
20
Study locations

Study Summary

A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

Conditions Studied

Biliary Tract Cancer

Interventions

  • DRUG Placebo
  • DRUG Capecitabine
  • DRUG Rilvegostomig
  • DRUG Gemcitabine/Cisplatin
  • DRUG S-1 [Tegafur/Oteracil/gimeracil]

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - Orange
  • Research Site - Stanford

Colorado

  • Research Site - Aurora
  • Research Site - Littleton

New York

  • Research Site - Commack
  • Research Site - Mineola

Alabama

  • Research Site - Birmingham

Arizona

  • Research Site - Phoenix

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Jacksonville

Georgia

  • Research Site - Atlanta

Trial Details

FieldValue
Enrollment Target 757 participants
Start Date 2023-12-04
Est. Completion 2030-05-03
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06109779

The ClinicalTrials.gov registry entry for NCT06109779 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 757 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (247% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT06109779 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Colorado, New York.

Frequently Asked Questions

What is clinical trial NCT06109779 about?

NCT06109779 is a clinical study titled "Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)". A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.

What is the current status of trial NCT06109779?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 757 participants. The study started on 2023-12-04. Estimated completion is 2030-05-03.

What conditions does trial NCT06109779 study?

This clinical trial studies the following conditions: Biliary Tract Cancer.

What interventions are being tested in trial NCT06109779?

The interventions under investigation include: Placebo (DRUG), Capecitabine (DRUG), Rilvegostomig (DRUG), Gemcitabine/Cisplatin (DRUG), S-1 [Tegafur/Oteracil/gimeracil] (DRUG).

Who is sponsoring clinical trial NCT06109779?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06109779 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Biliary Tract Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Biliary Tract Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.